A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302. [EXTENSION OF 23608 & 29662]
Phase of Trial: Phase III
Latest Information Update: 24 Dec 2013
At a glance
- Drugs Bapineuzumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational
- Sponsors Elan Pharmaceuticals; JANSSEN Alzheimer Immunotherapy
- 09 Aug 2012 Checked against EudraCT
- 06 Aug 2012 Status changed from recruiting to discontinued.
- 20 Mar 2012 Additional trial location (Austria) added as reported by ClinicalTrials.gov.